SLC4A11 Antibody

What is SLC4A11 and why are antibodies against it important in research?

SLC4A11 (solute carrier family 4 member 11) is an integral membrane protein highly expressed in the basolateral membrane of corneal endothelial cells . This protein functions as an H+/NH3/water transport protein critical for maintaining corneal fluid balance .

Antibodies against SLC4A11 are essential research tools because:

• They allow detection of endogenous SLC4A11 protein expression in various cell types

• They enable visualization of cellular localization through immunohistochemistry

• They support investigation of SLC4A11's role in corneal dystrophies, including congenital hereditary endothelial dystrophy (CHED) and Fuchs endothelial corneal dystrophy (FECD)

• They facilitate studying the molecular mechanisms underlying SLC4A11-related pathologies

Notably, mutations in SLC4A11 are directly linked to blinding corneal conditions, making antibodies against this protein invaluable for dissecting disease mechanisms and potentially developing therapeutic approaches .

What are the standard applications for SLC4A11 antibodies in research?

Based on the available research literature, SLC4A11 antibodies are commonly used in the following applications:

When conducting Western blot analysis, researchers typically detect SLC4A11 as a protein of approximately 99.6 kilodaltons . For optimal results, secondary antibodies such as goat anti-rabbit IgG conjugated with HRP, AP, FITC, or biotin can be used depending on the detection method .

How should researchers select the appropriate SLC4A11 antibody for their specific research questions?

When selecting an SLC4A11 antibody, researchers should consider several factors:

Antibody Specificity:

• Determine which SLC4A11 variant you need to detect (v1, v2, or v3)

• Research has shown that only v2 and v3 mRNA are present in human cornea, with v2 being most abundant (approximately four times more abundant than v3)

• Consider whether the antibody recognizes specific epitopes unique to particular variants

Immunogen Selection:

• Review the immunogen sequence to ensure it matches your region of interest

• Some antibodies are raised against synthesized peptides derived from internal regions of human SLC4A11

• Others use recombinant fusion proteins containing specific amino acid sequences (e.g., amino acids 1-180 of human SLC4A11)

Species Reactivity:

• Confirm the antibody reacts with your species of interest (commonly human, mouse, or rat)

• Cross-reactivity can be important for comparative studies

Validation Evidence:

• Look for antibodies with published validation data in applications similar to your planned experiments

• Scientific literature citations provide evidence of successful use in relevant research contexts

What controls should be included when using SLC4A11 antibodies?

Robust experimental design requires appropriate controls:

Positive Controls:

• HepG2 cells have been validated as positive controls for SLC4A11 expression

• 3T3 cells, RAW264.7 cells, and A549 cells have also been used as positive controls in Western blot analysis

Negative Controls:

• SLC4A11 knockout or knockdown cell lines (using shRNA targeting SLC4A11)

• Primary antibody omission control

• Isotype control (rabbit IgG at the same concentration)

• Peptide competition assay (pre-incubation with immunizing peptide)

Loading Controls:

• GAPDH is commonly used as a loading control for Western blot when studying SLC4A11

• Other standard loading controls like β-actin or α-tubulin may also be appropriate

How can researchers effectively use SLC4A11 antibodies in functional studies of corneal dystrophies?

For investigating SLC4A11's role in corneal dystrophies, researchers should consider:

Mutation-Specific Approaches:

• Generate cell lines harboring CHED-/FECD4-associated SLC4A11 mutations (SLC4A11 MU)

• Compare protein expression, localization, and function between wild-type and mutant SLC4A11

• Assess differences in cellular phenotypes including barrier function, proliferation, viability, and migration

Functional Readouts:

• Measure NH3-induced membrane conductance to assess SLC4A11 transport function

• Analyze cell growth and viability using real-time cell analyzers and trypan blue staining

• Evaluate apoptotic markers using Annexin V and TUNEL assays to detect cell death mechanisms

Expression System Selection:

• Human corneal endothelial cells (HCECs) represent a physiologically relevant system

• Xenopus laevis oocytes provide a low-background environment for studying transport functions

• HEK293 cells offer an alternative mammalian expression system with high transfection efficiency

What methodological approaches are effective for studying SLC4A11 variants using antibody-based techniques?

Research indicates that SLC4A11 has multiple variants with different expression patterns in human cornea. To study these variants:

Variant-Specific Detection:

• Use variant-specific antibodies that can distinguish between v1, v2, and v3

• Combine with RT-PCR and quantitative RT-PCR to correlate protein expression with transcript levels

• Consider that v2 protein is approximately four times more abundant than v3 in human corneal endothelium

Translation Initiation Site Analysis:

• Research has revealed that the second methionine (M36) in the open reading frame acts as a translation initiation site on SLC4A11 v2 in human cornea

• Western blot analysis using variant-specific antibodies can help determine which protein isoforms are expressed

Subcellular Localization Studies:

• Immunostaining of primary hCEnC and SLC4A11 WT hCEnC lines typically shows predominantly plasma membrane staining

• Some SLC4A11 may also be found in punctate subcellular structures with partial colocalization with mitochondrial markers like COX4

How can SLC4A11 antibodies help elucidate the protein's role in cell survival and apoptosis?

SLC4A11 plays a crucial role in cell survival, and antibodies are valuable tools for investigating this function:

Knockdown Studies:

• shRNA-mediated SLC4A11 depletion in human corneal endothelial cells (HCECs) leads to increased apoptosis

• Researchers can use SLC4A11 antibodies to confirm knockdown efficiency via Western blot

• Two different shRNA targets have been validated:

  • shRNA1: 5′-GCCTGAAAGAGAAACCATT-3′

  • shRNA2: 5′-GCACAGAGGAGGAATTCAA-3′

Apoptotic Pathway Analysis:

• SLC4A11 knockdown affects apoptotic gene expression, which can be assessed using RT² Profiler PCR array for human apoptosis

• Western blot with phospho-specific antibodies can help determine activation of apoptotic pathways

Cell Growth Assessment:

• Real-time cell analyzer (RTCA) instruments can monitor cell growth continuously while SLC4A11 expression is verified by antibody-based techniques

• This approach allows correlation between SLC4A11 expression levels and cell growth parameters

What approaches can researchers use to investigate SLC4A11 transport function in relation to protein expression?

SLC4A11 functions as a H+/NH3/water transport protein, and researchers can correlate protein expression with transport function using:

Transport Assays:

• NH3-H+ cotransport can be measured in cells expressing SLC4A11

• Cell swelling assays in response to hypo-osmotic challenge can assess water permeability

• SLC4A11 antibodies can confirm protein expression levels in parallel with functional assays

Electrophysiological Measurements:

• Membrane potential changes in response to NH4Cl can differentiate wild-type from mutant or deficient cells

• SLC4A11 WT cells typically depolarize upon induction with 10mM NH4Cl, while SLC4A11-/- cells hyperpolarize

• Expression levels determined by antibody detection can be correlated with electrophysiological responses

Structure-Function Analysis:

• Structural homology models of different SLC4A11 variants can be combined with antibody-detected expression data to correlate structure with function

• This approach is particularly valuable for understanding how mutations affect both expression and function

How can researchers integrate SLC4A11 antibody data with transcriptomic analyses?

Integration of protein-level data (via antibodies) with transcriptomic analyses provides comprehensive insights:

Correlation Analysis:

• RNA sequencing of corneal tissue can identify genes with altered expression in SLC4A11-deficient models

• Antibody-based protein quantification can validate whether changes in mRNA levels correspond to protein expression changes

• This approach has revealed that SLC4A11 deficiency affects genes involved in:

  • Extracellular region functions

  • Cytoskeletal organization

  • Cell adhesion

  • Plasma membrane functions

Pathway Analysis:

• Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of transcriptomic data

• Protein interaction networks derived from antibody-based co-immunoprecipitation studies

• Combined analyses can identify functional clusters affected by SLC4A11 status, including:

  • Cell fate and development

  • Extracellular matrix and cell adhesion

  • Cytoskeleton

  • Ion homeostasis

  • Energy metabolism

What methodological challenges exist when using SLC4A11 antibodies in complex tissue samples?

Working with complex tissue samples presents several challenges:

Tissue Preparation Considerations:

• Fresh corneal tissue preservation methods can affect antibody epitope accessibility

• Paraffin embedding may require antigen retrieval techniques for optimal SLC4A11 detection

• Cryosectioning may better preserve epitopes but presents challenges for membrane protein retention

Signal Specificity:

• SLC4A11 antibodies must be validated in tissues with known SLC4A11 knockout/knockdown status

• Background signal can be problematic in corneal tissue due to high collagen content

• Autofluorescence of corneal tissue may interfere with immunofluorescence detection

Quantification Approaches:

• Western blot quantification from tissue extracts requires careful normalization

• Immunohistochemistry quantification should account for regional differences in SLC4A11 expression

• Consider laser capture microdissection to isolate specific cell layers (epithelium versus endothelium) prior to antibody-based analyses

How might emerging antibody technologies advance SLC4A11 research?

Emerging technologies offer new opportunities for SLC4A11 research:

Super-resolution Microscopy:

• Advanced imaging techniques combined with highly specific SLC4A11 antibodies can reveal submembrane localization patterns

• This approach may help understand the relationship between SLC4A11 and other membrane components

Proximity Labeling:

• Antibody-based BioID or APEX2 proximity labeling can identify proteins that interact with SLC4A11

• This helps map the protein interaction network around SLC4A11 in its native cellular environment

Single-cell Analysis:

• Single-cell proteomics combined with SLC4A11 antibodies can reveal cell-to-cell variability in expression

• This approach may help identify subpopulations of cells with different SLC4A11 expression patterns in healthy and diseased corneas

What is the potential for therapeutic applications based on SLC4A11 antibody research?

While primarily research tools, SLC4A11 antibodies contribute to therapeutic development:

Biomarker Development:

• SLC4A11 antibodies can help establish whether protein expression levels correlate with disease progression

• This may lead to diagnostic tools for early detection of corneal dystrophies

Drug Target Validation:

• Antibody-based studies help validate SLC4A11 as a drug target by confirming its role in disease mechanisms

• Understanding protein expression patterns guides the development of small molecule modulators

Gene Therapy Monitoring:

• As gene therapy approaches for SLC4A11-related disorders develop, antibodies will be essential for monitoring therapeutic protein expression

• This helps establish correlations between restored protein levels and functional outcomes

By incorporating these advanced research applications, scientists can leverage SLC4A11 antibodies to further our understanding of corneal physiology and pathology, potentially leading to new therapeutic strategies for SLC4A11-related corneal dystrophies.